Gavin C Donaldson
Overview
Explore the profile of Gavin C Donaldson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
3806
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
MacLeod M, Knott K, Allinson J, Finney L, Wiseman D, Ritchie A, et al.
Am J Respir Crit Care Med
. 2024 Dec;
PMID: 39680915
Rationale: Unrecognised coronary artery disease (CAD) may contribute to adverse outcomes in chronic obstructive pulmonary disease (COPD). Improved identification of at-risk groups could inform better preventative care. We aimed to...
2.
Wiseman D, Thwaites R, Ritchie A, Finney L, Macleod M, Kamal F, et al.
Am J Respir Crit Care Med
. 2024 Mar;
210(8):994-1001.
PMID: 38502541
Respiratory syncytial virus (RSV) is a common global respiratory virus that is increasingly recognized as a major pathogen in frail older adults and as a cause of chronic obstructive pulmonary...
3.
Meldrum O, Donaldson G, Narayana J, Ivan F, Jaggi T, Mac Aogain M, et al.
Am J Respir Crit Care Med
. 2024 Feb;
210(3):298-310.
PMID: 38315959
Progressive lung function loss is recognized in chronic obstructive pulmonary disease (COPD); however, no study concurrently evaluates how accelerated lung function decline relates to mucus properties and the microbiome in...
4.
Ritchie A, Donaldson G, Hoffman E, Allinson J, Bloom C, Bolton C, et al.
Am J Respir Crit Care Med
. 2024 Jan;
209(10):1208-1218.
PMID: 38175920
Chronic obstructive pulmonary disease (COPD) due to tobacco smoking commonly presents when extensive lung damage has occurred. We hypothesized that structural change would be detected early in the natural history...
5.
Finney L, Avey S, Wiseman D, Rowe A, Loza M, Branigan P, et al.
ERJ Open Res
. 2023 Dec;
9(6).
PMID: 38152081
Background: Early and accurate identification of acute exacerbations of COPD may lead to earlier treatment and prevent hospital admission. Electronic diaries have been developed for symptom monitoring and accelerometers to...
6.
Bertels X, Edris A, Garcia-Aymerich J, Faner R, Meteran H, Sigsgaard T, et al.
BMJ Open Respir Res
. 2023 Aug;
10(1).
PMID: 37612099
Background: The prevalence and clinical profile of asthma with airflow obstruction (AO) remain uncertain. We aimed to phenotype AO in population- and clinic-based cohorts. Methods: This cross-sectional multicohort study included...
7.
Bhatt S, Agusti A, Bafadhel M, Christenson S, Bon J, Donaldson G, et al.
Am J Respir Crit Care Med
. 2023 Aug;
208(10):1026-1041.
PMID: 37560988
Chronic obstructive pulmonary disease is a major health problem with a high prevalence, a rising incidence, and substantial morbidity and mortality. Its course is punctuated by acute episodes of increased...
8.
Allinson J, Vlies B, Brill S, Law M, Burnside G, Finney L, et al.
Am J Respir Crit Care Med
. 2023 Jul;
208(5):549-558.
PMID: 37450935
Chronic obstructive pulmonary disease (COPD) exacerbations are a major cause of morbidity and mortality, and preventing them is a key treatment target. Long-term macrolide treatment is effective at reducing exacerbations,...
9.
Liang W, Yang Y, Gong S, Wei M, Ma Y, Feng R, et al.
Cell Host Microbe
. 2023 May;
31(6):1054-1070.e9.
PMID: 37207649
Progressive lung function decline is a hallmark of chronic obstructive pulmonary disease (COPD). Airway dysbiosis occurs in COPD, but whether it contributes to disease progression remains unknown. Here, we show,...
10.
Shah P, Orton C, Grinsztejn B, Donaldson G, Crabtree Ramirez B, Tonkin J, et al.
Lancet Respir Med
. 2022 Dec;
11(5):415-424.
PMID: 36528039
Background: COVID-19 has overwhelmed health services globally. Oral antiviral therapies are licensed worldwide, but indications and efficacy rates vary. We aimed to evaluate the safety and efficacy of oral favipiravir...